|
WO2012121939A2
|
|
Aminopyrazine compounds
|
|
WO2010126960A1
|
|
Pyrrolotriazine compounds
|
|
US2010041642A1
|
|
Urea inhibitors of map kinases
|
|
WO2009085042A1
|
|
Methods and systems for improving free energy estimation of fragments
|
|
US2009171642A1
|
|
Methods and systems for improving free energy estimation of fragments
|
|
US2009094012A1
|
|
Methods and systems for grand canonical competitive simulation of molecular fragments
|
|
WO2009048460A1
|
|
Methods and systems for grand canonical competitive simulation of molecular fragments
|
|
US2008280891A1
|
|
Anti-cancer agents and uses thereof
|
|
US2007185098A1
|
|
Inhibitors of protein kinases
|
|
WO2008008059A1
|
|
Anti-cancer agents ans uses thereof
|
|
CA2589274A1
|
|
Inhibitors of protein kinases
|
|
US2006167247A1
|
|
Urea inhibitors of MAP kinases
|
|
US2007016374A1
|
|
Method, system, and computer program product for identifying binding conformations of chemical fragments and biological molecules
|
|
EP1763814A2
|
|
Identification of ligands for macromolecules
|
|
US2006270686A1
|
|
Anti-cancer agents and uses thereof
|
|
US2005123995A1
|
|
Methods and systems for analyzing and determining ligand-residue interaction
|
|
EP1644860A2
|
|
Method and computer program product for drug discovery using weighted grand canonical metropolis monte carlo sampling
|
|
EP1639514A2
|
|
Efficient methods for multibody simulations
|
|
US2005222776A1
|
|
Method for fragment preparation
|
|
US2004220746A1
|
|
Methods and systems for preparing virtual representations of molecules
|
